home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Exscientia plc

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

October 16, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

October 09, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

August 28, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Business Update for Second Quarter and First Half 2024

August 15, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

July 18, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery

July 10, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

June 06, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia to Present at Upcoming Investor Conferences in June

May 30, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Business Update for First Quarter 2024

May 21, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024

May 14, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Business and Financial Update for the Full Year 2023

March 21, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia to Report Full Year 2023 Financial Results on March 21, 2024

March 14, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia to Present at Upcoming Investor Conferences in March

February 28, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients

February 07, 2024

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme

December 21, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza

December 05, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference

November 21, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Business Update for Third Quarter 2023

November 09, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023

November 02, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Parker Moss to Join Exscientia as EVP, Corporate Development

October 17, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023

October 16, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Details Pipeline Prioritisation Strategy

October 03, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany

September 20, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia to Present at Upcoming Investor Conferences in September

August 31, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Business Update for Second Quarter and First Half of 2023

August 10, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours

July 10, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

June 06, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Business Update for First Quarter 2023

May 24, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe

May 22, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023

May 17, 2023

From Exscientia plc

Via Business Wire

Tickers EXAI

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com